Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple sclerosis
Biotech
Contineum-J&J drug fails to improve vision in phase 2 MS trial
The Johnson & Johnson-partnered asset failed to trigger any significant change in vision acuity for MS patients.
Gabrielle Masson
Nov 20, 2025 5:26pm
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor
Nov 10, 2025 6:26am
Zenas autoimmune drug prompts 95% drop in lesions in MS study
Oct 27, 2025 9:25am
Diabetes drug soothes brain inflammation in female mice with MS
Oct 15, 2025 6:16pm
Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay
Sep 22, 2025 8:00am
Thermo Fisher debuts protein panel for neurodegeneration R&D
Sep 16, 2025 12:00pm
